Hey y'all, I'm feeling pretty lazy tonight and mel
Post# of 148164
(Total Views: 824)
Posted On: 02/09/2022 7:55:43 PM
Hey y'all, I'm feeling pretty lazy tonight and melsdollars had a killer post already.
(Great work mels)
So instead of coming up with something all on my own, which seems taxing, I decided to just turn Mels post into a Respert post. Way less effort since all the hard work is done. So forget everything you just read and please enjoy this completely original and unique take on our current situation.
Re: Collaboration –
Of all the theories about what's going on behind the scenes at Cytodyn, a potential partnership with Qilu Pharma seems to make the most sense. It's a jigsaw of a puzzle, but the pieces do seem to fit together. And as I’ve been teaching the local middle school boys I mentor, if it doesn’t want to fit you just keep pushing until it goes in.
Qilu is apparently a Chinese pharma company doing business in over 70 countries, but I’m not fully convinced it isn’t just three Naders standing on each other’s shoulders and wearing a trench coat. I mean, they’re basically saying they want to partner with companies that have Leronlimab. If you read between the trench coat, that is.
You couldn’t draw it up better if you were Gary Larson. And if you don’t get the reference I’d suggest you look it up, ya dilberts.
(You just got comic strip burned)
Qilu is the manufacturer or Carboplatin, the drug Leronlimab is in trials with at MD Anderson Cancer Center.
Boom.
Dr. Ray returned to Cytodyn as VP of Licensing and Business Development in November. Dr. Ray formerly worked for Qilu Phama as their Senior VP of Licensing. He negotiated Qilu's licensing deal with Arbutus Biopharma. I normally don’t allow butt stuff, but Arbutus is spelled with only one T so I’m allowing it. (But watch yourself counselor)
Boom.
Sidely Austin helped establish the company Arbutus Biopharma which eventually partnered with Qilu.
Double Boom.
Sidley Austin is counsel for Xynomic Pharma, handling their merger with Bison Capital. Xynomic's Vice President is Yong Cui, formerly VP of R&D for Qilu.
I like the cut of this Bison Capital’s jib. Strong name. Time for a quick tangent.
There’s a restaurant in Metro Detroit that specializes in wild game, eschewing the usual sirloins and strips for meats like Bison or Emu. Two memories crept up as I read the word Bison. The first is that Emu tastes exactly like filet mignon. The second memory is that it was at that restaurant that I broke out a dumb joke for the first time that has become one of my favorites to employ amongst friends and coworkers: My female teammate, who happened to be only a few years older than me, ordered her meal and I realized I’d be ordering the same thing. So when the waiter got to me and asked what I wanted, I responded with “I’ll have the same thing my mom is having” and it went over about as well as you can imagine. But I loved it, which is all that mattered.
For my own personal enjoyment it's right up there with “could you seat us somewhere romantic?” when eating out with buddies. Ok, back to the story.
Oh, and I almost forgot…
Boom.
Sidley was counsel of record in a patent dispute, Janssen v. Qilu. By the way, that’s not a spelling error. They really use two esses when spelling their own name like a bunch of morons. I hope they lost that lawsuit.
Gavel Boom.
Sidley has offices all over the world, including Beijing and Hong Kong.
Geography Boom, bitches.
- - - -
In my opinion, a potential partnership has been in the works for some time and if you can’t see it, to quote the great investor Robert Diggs of Wu-Tang Financial, you couldn’t cut your way out of a wet paper bag…with scissors in your hand.
FACT: Dr. Ray worked for Cytodyn before. He would not return unless there was a viable product for development.
FACT: Dr. Scott Kelly specifically mentioned China when discussing potential partnerships in the December conference call.
FACT-ADJACENT: The Leronlimab trial with Qilu's Carboplatin could be a 'proof of concept' situation. You know, the old “let me get a little bump to make sure you’ve got the good stuff.” Then just a few weeks later they’re offering ZJ’s under the overpass to try to afford just a little more of that sweet, sweet Leronlimab. Now they’re ready to really pony up.
What’s a ZJ?
If you have to ask, you can’t afford it.
Now, consider that Sidley Austin could have been in discussions with Cytodyn regarding collaborations all the way back when the 13d(bags) nonsense started. So retaining Sidley to defend the 13d(bag) takeover was a lucky happenstance that Cytodyn took advantage of.
Like when you’re out in public wearing your “I’m Respert24” t-shirt and the ladies just throw themselves at you. You don’t say, “hey, I’m not Respert, I’m just a fan”. No, you jokingly say “no butt stuff” while laughing, and then you invite them back to the hotel where you’ll double back on your word.
With consent of course, ya dilberts.
Anyway, it seems clear now that Pourhassan was voted back in to maintain the status quo, until the next phase. Which, since nobody has named it yet, we’ll call Phase 2: Electric Boogaloo.
We are now in a quiet period, so stop posting about how you’ve emailed someone from Cytodyn and they’ve yet to respond. Yeah, of course they haven’t responded. They can’t. Not until the ink is dry on the deal. Until then they have to shut up. In fact, maybe moving Nader on was originally going to happen after the ink was dry, because he’s said numerous times that he’d move on when the time was right, but then they realized that loose lips sink ships and Nader has been rocking flabby old-lady-tits-type-lips (medical term) for years now and was too risky to keep around.
Listen, these are just facts. Melsdollars knows what I’m talking about.
All will be clear very soon. In the meantime, strong and long CYDY!
Respertfully yours,
Evening Respert24
(Great work mels)
So instead of coming up with something all on my own, which seems taxing, I decided to just turn Mels post into a Respert post. Way less effort since all the hard work is done. So forget everything you just read and please enjoy this completely original and unique take on our current situation.
Re: Collaboration –
Of all the theories about what's going on behind the scenes at Cytodyn, a potential partnership with Qilu Pharma seems to make the most sense. It's a jigsaw of a puzzle, but the pieces do seem to fit together. And as I’ve been teaching the local middle school boys I mentor, if it doesn’t want to fit you just keep pushing until it goes in.
Qilu is apparently a Chinese pharma company doing business in over 70 countries, but I’m not fully convinced it isn’t just three Naders standing on each other’s shoulders and wearing a trench coat. I mean, they’re basically saying they want to partner with companies that have Leronlimab. If you read between the trench coat, that is.
You couldn’t draw it up better if you were Gary Larson. And if you don’t get the reference I’d suggest you look it up, ya dilberts.
(You just got comic strip burned)
Qilu is the manufacturer or Carboplatin, the drug Leronlimab is in trials with at MD Anderson Cancer Center.
Boom.
Dr. Ray returned to Cytodyn as VP of Licensing and Business Development in November. Dr. Ray formerly worked for Qilu Phama as their Senior VP of Licensing. He negotiated Qilu's licensing deal with Arbutus Biopharma. I normally don’t allow butt stuff, but Arbutus is spelled with only one T so I’m allowing it. (But watch yourself counselor)
Boom.
Sidely Austin helped establish the company Arbutus Biopharma which eventually partnered with Qilu.
Double Boom.
Sidley Austin is counsel for Xynomic Pharma, handling their merger with Bison Capital. Xynomic's Vice President is Yong Cui, formerly VP of R&D for Qilu.
I like the cut of this Bison Capital’s jib. Strong name. Time for a quick tangent.
There’s a restaurant in Metro Detroit that specializes in wild game, eschewing the usual sirloins and strips for meats like Bison or Emu. Two memories crept up as I read the word Bison. The first is that Emu tastes exactly like filet mignon. The second memory is that it was at that restaurant that I broke out a dumb joke for the first time that has become one of my favorites to employ amongst friends and coworkers: My female teammate, who happened to be only a few years older than me, ordered her meal and I realized I’d be ordering the same thing. So when the waiter got to me and asked what I wanted, I responded with “I’ll have the same thing my mom is having” and it went over about as well as you can imagine. But I loved it, which is all that mattered.
For my own personal enjoyment it's right up there with “could you seat us somewhere romantic?” when eating out with buddies. Ok, back to the story.
Oh, and I almost forgot…
Boom.
Sidley was counsel of record in a patent dispute, Janssen v. Qilu. By the way, that’s not a spelling error. They really use two esses when spelling their own name like a bunch of morons. I hope they lost that lawsuit.
Gavel Boom.
Sidley has offices all over the world, including Beijing and Hong Kong.
Geography Boom, bitches.
- - - -
In my opinion, a potential partnership has been in the works for some time and if you can’t see it, to quote the great investor Robert Diggs of Wu-Tang Financial, you couldn’t cut your way out of a wet paper bag…with scissors in your hand.
FACT: Dr. Ray worked for Cytodyn before. He would not return unless there was a viable product for development.
FACT: Dr. Scott Kelly specifically mentioned China when discussing potential partnerships in the December conference call.
FACT-ADJACENT: The Leronlimab trial with Qilu's Carboplatin could be a 'proof of concept' situation. You know, the old “let me get a little bump to make sure you’ve got the good stuff.” Then just a few weeks later they’re offering ZJ’s under the overpass to try to afford just a little more of that sweet, sweet Leronlimab. Now they’re ready to really pony up.
What’s a ZJ?
If you have to ask, you can’t afford it.
Now, consider that Sidley Austin could have been in discussions with Cytodyn regarding collaborations all the way back when the 13d(bags) nonsense started. So retaining Sidley to defend the 13d(bag) takeover was a lucky happenstance that Cytodyn took advantage of.
Like when you’re out in public wearing your “I’m Respert24” t-shirt and the ladies just throw themselves at you. You don’t say, “hey, I’m not Respert, I’m just a fan”. No, you jokingly say “no butt stuff” while laughing, and then you invite them back to the hotel where you’ll double back on your word.
With consent of course, ya dilberts.
Anyway, it seems clear now that Pourhassan was voted back in to maintain the status quo, until the next phase. Which, since nobody has named it yet, we’ll call Phase 2: Electric Boogaloo.
We are now in a quiet period, so stop posting about how you’ve emailed someone from Cytodyn and they’ve yet to respond. Yeah, of course they haven’t responded. They can’t. Not until the ink is dry on the deal. Until then they have to shut up. In fact, maybe moving Nader on was originally going to happen after the ink was dry, because he’s said numerous times that he’d move on when the time was right, but then they realized that loose lips sink ships and Nader has been rocking flabby old-lady-tits-type-lips (medical term) for years now and was too risky to keep around.
Listen, these are just facts. Melsdollars knows what I’m talking about.
All will be clear very soon. In the meantime, strong and long CYDY!
Respertfully yours,
Evening Respert24
(21)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼